Globus Medical (GMED) EBIT (2011 - 2026)

Globus Medical has reported EBIT for 16 years, with the latest figure at $150.4 million in Q1 2026.

• For the quarter ending Q1 2026, EBIT rose 55.03% year-over-year to $150.4 million; the trailing twelve-month figure through Mar 2026 stood at $533.2 million (up 109.1% YoY), and the FY2025 full-year result was $479.8 million, up 189.06% from the prior year.
• EBIT for Q1 2026 stood at $150.4 million, down from $169.3 million in the prior quarter.
• The five-year high for EBIT was $169.3 million in Q4 2025, with the low at $404000.0 in Q3 2023.
• Historically, EBIT has averaged $68.1 million across 5 years, with a median of $59.7 million in 2022.
• Annual changes were most pronounced in 2023 — EBIT sank 99.32% — and 2024, when it soared 11805.45%.
• Globus Medical's EBIT stood at $54.0 million in 2022, then plunged by 81.26% to $10.1 million in 2023, then jumped by 495.42% to $60.3 million in 2024, then jumped by 180.95% to $169.3 million in 2025, then fell by 11.19% to $150.4 million in 2026.
• The last three EBIT figures came in at $150.4 million (Q1 2026), $169.3 million (Q4 2025), and $137.4 million (Q3 2025), per Business Quant data.